PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17950515-3	2008	In the present, we reported that deoxyschizandrin and gamma-schizandrin could induce apoptosis in human promyelocytic leukemia cells (HL-60), as characterized by DNA fragmentation and poly (ADP) ribose polymerase (PARP) cleavage.	schizandrin A	33-49	poly(ADP-ribose) polymerase 1	Homo sapiens	184-212
17950515-3	2008	In the present, we reported that deoxyschizandrin and gamma-schizandrin could induce apoptosis in human promyelocytic leukemia cells (HL-60), as characterized by DNA fragmentation and poly (ADP) ribose polymerase (PARP) cleavage.	schizandrin A	33-49	poly(ADP-ribose) polymerase 1	Homo sapiens	214-218
17950515-4	2008	Further molecular analysis showed that deoxyschizandrin and gamma-schizandrin caused the loss of mitochondrial membrane potential (DeltaPsim), cytochrome c release from mitochondrion to cytosol, truncation of Bid protein, and activation of caspase-3 and -9.	schizandrin A	39-55	cytochrome c, somatic	Homo sapiens	143-155
17950515-4	2008	Further molecular analysis showed that deoxyschizandrin and gamma-schizandrin caused the loss of mitochondrial membrane potential (DeltaPsim), cytochrome c release from mitochondrion to cytosol, truncation of Bid protein, and activation of caspase-3 and -9.	schizandrin A	39-55	BH3 interacting domain death agonist	Homo sapiens	209-212
17950515-4	2008	Further molecular analysis showed that deoxyschizandrin and gamma-schizandrin caused the loss of mitochondrial membrane potential (DeltaPsim), cytochrome c release from mitochondrion to cytosol, truncation of Bid protein, and activation of caspase-3 and -9.	schizandrin A	39-55	caspase 3	Homo sapiens	240-256
17129588-3	2007	The activities of 5 dibenzocyclooctadiene lignans (schisandrin A, schisandrin B, schisantherin A, schisandrol A, and schisandrol B) to reverse MRP1-mediated drug resistance were tested using HL60/Adriamycin (ADR) and HL60/Multidrug resistance-associated protein (MRP), two human promyelocytic leukemia cell lines with overexpression of MRP1 but not P-gp.	schizandrin A	51-64	ATP binding cassette subfamily C member 1	Homo sapiens	143-147
17566147-9	2007	These results demonstrated that deoxyschizandrin effectively inhibited the P-gp-mediated efflux in Caco-2 cells, suggesting they could potentially increase the absorption of drugs that can act as a P-gp substrate.	schizandrin A	32-48	phosphoglycolate phosphatase	Homo sapiens	75-79
17566147-9	2007	These results demonstrated that deoxyschizandrin effectively inhibited the P-gp-mediated efflux in Caco-2 cells, suggesting they could potentially increase the absorption of drugs that can act as a P-gp substrate.	schizandrin A	32-48	phosphoglycolate phosphatase	Homo sapiens	198-202
17129588-3	2007	The activities of 5 dibenzocyclooctadiene lignans (schisandrin A, schisandrin B, schisantherin A, schisandrol A, and schisandrol B) to reverse MRP1-mediated drug resistance were tested using HL60/Adriamycin (ADR) and HL60/Multidrug resistance-associated protein (MRP), two human promyelocytic leukemia cell lines with overexpression of MRP1 but not P-gp.	schizandrin A	51-64	ATP binding cassette subfamily C member 1	Homo sapiens	217-261
17129588-3	2007	The activities of 5 dibenzocyclooctadiene lignans (schisandrin A, schisandrin B, schisantherin A, schisandrol A, and schisandrol B) to reverse MRP1-mediated drug resistance were tested using HL60/Adriamycin (ADR) and HL60/Multidrug resistance-associated protein (MRP), two human promyelocytic leukemia cell lines with overexpression of MRP1 but not P-gp.	schizandrin A	51-64	ATP binding cassette subfamily C member 1	Homo sapiens	143-146
17129588-3	2007	The activities of 5 dibenzocyclooctadiene lignans (schisandrin A, schisandrin B, schisantherin A, schisandrol A, and schisandrol B) to reverse MRP1-mediated drug resistance were tested using HL60/Adriamycin (ADR) and HL60/Multidrug resistance-associated protein (MRP), two human promyelocytic leukemia cell lines with overexpression of MRP1 but not P-gp.	schizandrin A	51-64	ATP binding cassette subfamily C member 1	Homo sapiens	336-340
17129588-3	2007	The activities of 5 dibenzocyclooctadiene lignans (schisandrin A, schisandrin B, schisantherin A, schisandrol A, and schisandrol B) to reverse MRP1-mediated drug resistance were tested using HL60/Adriamycin (ADR) and HL60/Multidrug resistance-associated protein (MRP), two human promyelocytic leukemia cell lines with overexpression of MRP1 but not P-gp.	schizandrin A	51-64	ATP binding cassette subfamily B member 1	Homo sapiens	349-353
33232930-9	2021	GTS, STL, ginsenosides Rd and Rb1, and schisandrol B were potent inhibitors of BCRP and showed different degrees of inhibition on the transport of ginsenosides Re and Rg1, methylophiopogonanone B, and schizandrin A via BCRP.	schizandrin A	201-214	RB transcriptional corepressor 1	Sus scrofa	30-33
34550868-10	2021	The wound healing, Hoechst 33342/PI, and western blot assays confirmed that SchA significantly down-regulated EGFR, PIK3R1, and MMP9, but up-regulated cleaved-caspase 3, thus inhibiting the migration and promoting the apoptosis of MDA-MB-231 cells.	schizandrin A	76-80	epidermal growth factor receptor	Homo sapiens	110-114
34812475-0	2022	Schisandrin A protects against isoproterenol-induced chronic heart failure via miR-155.	schizandrin A	0-13	microRNA 155	Rattus norvegicus	79-86
34812475-12	2022	In addition, Sch A inhibited ISO-induced upregulated expressions of atrial natriuretic peptide, B-type natriuretic peptide, B-myosin heavy chain and miR-155 in myocardial tissue.	schizandrin A	13-18	natriuretic peptide A	Rattus norvegicus	68-94
34812475-12	2022	In addition, Sch A inhibited ISO-induced upregulated expressions of atrial natriuretic peptide, B-type natriuretic peptide, B-myosin heavy chain and miR-155 in myocardial tissue.	schizandrin A	13-18	microRNA 155	Rattus norvegicus	149-156
34812475-14	2022	Sch A inhibited the levels of miR-155, alpha-SMA and the phosphorylation levels of AKT and cyclic AMP response-element binding protein (CREB) in ISO-induced NRVMs, which was reversed by the upregulation of miR-155.	schizandrin A	0-5	microRNA 155	Rattus norvegicus	30-37
34812475-14	2022	Sch A inhibited the levels of miR-155, alpha-SMA and the phosphorylation levels of AKT and cyclic AMP response-element binding protein (CREB) in ISO-induced NRVMs, which was reversed by the upregulation of miR-155.	schizandrin A	0-5	AKT serine/threonine kinase 1	Rattus norvegicus	83-86
34812475-14	2022	Sch A inhibited the levels of miR-155, alpha-SMA and the phosphorylation levels of AKT and cyclic AMP response-element binding protein (CREB) in ISO-induced NRVMs, which was reversed by the upregulation of miR-155.	schizandrin A	0-5	cAMP responsive element binding protein 1	Rattus norvegicus	91-134
34812475-14	2022	Sch A inhibited the levels of miR-155, alpha-SMA and the phosphorylation levels of AKT and cyclic AMP response-element binding protein (CREB) in ISO-induced NRVMs, which was reversed by the upregulation of miR-155.	schizandrin A	0-5	cAMP responsive element binding protein 1	Rattus norvegicus	136-140
34812475-14	2022	Sch A inhibited the levels of miR-155, alpha-SMA and the phosphorylation levels of AKT and cyclic AMP response-element binding protein (CREB) in ISO-induced NRVMs, which was reversed by the upregulation of miR-155.	schizandrin A	0-5	microRNA 155	Rattus norvegicus	206-213
34812475-15	2022	Schisandrin A mediated the AKT/CREB signaling pathway to prevent CHF by regulating the expression of miR-155, which may shed light on a possible therapeutic target for CHF.	schizandrin A	0-13	AKT serine/threonine kinase 1	Rattus norvegicus	27-30
34812475-15	2022	Schisandrin A mediated the AKT/CREB signaling pathway to prevent CHF by regulating the expression of miR-155, which may shed light on a possible therapeutic target for CHF.	schizandrin A	0-13	cAMP responsive element binding protein 1	Rattus norvegicus	31-35
34812475-15	2022	Schisandrin A mediated the AKT/CREB signaling pathway to prevent CHF by regulating the expression of miR-155, which may shed light on a possible therapeutic target for CHF.	schizandrin A	0-13	microRNA 155	Rattus norvegicus	101-108
34550868-10	2021	The wound healing, Hoechst 33342/PI, and western blot assays confirmed that SchA significantly down-regulated EGFR, PIK3R1, and MMP9, but up-regulated cleaved-caspase 3, thus inhibiting the migration and promoting the apoptosis of MDA-MB-231 cells.	schizandrin A	76-80	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	116-122
34550868-10	2021	The wound healing, Hoechst 33342/PI, and western blot assays confirmed that SchA significantly down-regulated EGFR, PIK3R1, and MMP9, but up-regulated cleaved-caspase 3, thus inhibiting the migration and promoting the apoptosis of MDA-MB-231 cells.	schizandrin A	76-80	matrix metallopeptidase 9	Homo sapiens	128-132
34214019-8	2021	RESULTS: Sch A treatment effectively improved spatial learning and memory ability and suppressed apoptosis in the brain tissues of APP/PS1 mice.	schizandrin A	9-14	presenilin 1	Mus musculus	135-138
34214019-9	2021	APP/PS1 mice exhibited an increase in the levels of Abeta1-42 (2367.9 +- 431.1 pg/mg) and Abeta1-40 (1753.3 +- 253.4 pg/mg), which was abolished by Sch A treatment.	schizandrin A	148-153	presenilin 1	Mus musculus	4-7
34214019-10	2021	Moreover, Sch A treatment repressed the proportions of iNOS+/Iba-1+ cells and IL-6 expression, while enhanced the proportions of Arg-1+/Iba-1+ cells and IL-10 expression in APP/PS1 mice.	schizandrin A	10-15	nitric oxide synthase 2, inducible	Mus musculus	55-59
34214019-10	2021	Moreover, Sch A treatment repressed the proportions of iNOS+/Iba-1+ cells and IL-6 expression, while enhanced the proportions of Arg-1+/Iba-1+ cells and IL-10 expression in APP/PS1 mice.	schizandrin A	10-15	induction of brown adipocytes 1	Mus musculus	61-66
34214019-10	2021	Moreover, Sch A treatment repressed the proportions of iNOS+/Iba-1+ cells and IL-6 expression, while enhanced the proportions of Arg-1+/Iba-1+ cells and IL-10 expression in APP/PS1 mice.	schizandrin A	10-15	interleukin 6	Mus musculus	78-82
34214019-10	2021	Moreover, Sch A treatment repressed the proportions of iNOS+/Iba-1+ cells and IL-6 expression, while enhanced the proportions of Arg-1+/Iba-1+ cells and IL-10 expression in APP/PS1 mice.	schizandrin A	10-15	arginase, liver	Mus musculus	129-134
34214019-10	2021	Moreover, Sch A treatment repressed the proportions of iNOS+/Iba-1+ cells and IL-6 expression, while enhanced the proportions of Arg-1+/Iba-1+ cells and IL-10 expression in APP/PS1 mice.	schizandrin A	10-15	induction of brown adipocytes 1	Mus musculus	136-141
34214019-10	2021	Moreover, Sch A treatment repressed the proportions of iNOS+/Iba-1+ cells and IL-6 expression, while enhanced the proportions of Arg-1+/Iba-1+ cells and IL-10 expression in APP/PS1 mice.	schizandrin A	10-15	interleukin 10	Mus musculus	153-158
34214019-10	2021	Moreover, Sch A treatment repressed the proportions of iNOS+/Iba-1+ cells and IL-6 expression, while enhanced the proportions of Arg-1+/Iba-1+ cells and IL-10 expression in APP/PS1 mice.	schizandrin A	10-15	presenilin 1	Mus musculus	177-180
34214019-11	2021	In vitro, Sch A treatment reduced the proportions of CD16/32+ cells, iNOS expression and IL-6 levels (25.7 +- 5.3 pg/mL) repressed M1 polarisation, and enhanced the proportions of CD206 cells, Arg-1 expression and IL-10 levels (75.9 +- 12.8 pg/mL) in BV2 cells.	schizandrin A	10-15	Fc receptor, IgG, low affinity III	Mus musculus	53-60
34214019-11	2021	In vitro, Sch A treatment reduced the proportions of CD16/32+ cells, iNOS expression and IL-6 levels (25.7 +- 5.3 pg/mL) repressed M1 polarisation, and enhanced the proportions of CD206 cells, Arg-1 expression and IL-10 levels (75.9 +- 12.8 pg/mL) in BV2 cells.	schizandrin A	10-15	nitric oxide synthase 2, inducible	Mus musculus	69-73
34214019-11	2021	In vitro, Sch A treatment reduced the proportions of CD16/32+ cells, iNOS expression and IL-6 levels (25.7 +- 5.3 pg/mL) repressed M1 polarisation, and enhanced the proportions of CD206 cells, Arg-1 expression and IL-10 levels (75.9 +- 12.8 pg/mL) in BV2 cells.	schizandrin A	10-15	interleukin 6	Mus musculus	89-93
34214019-11	2021	In vitro, Sch A treatment reduced the proportions of CD16/32+ cells, iNOS expression and IL-6 levels (25.7 +- 5.3 pg/mL) repressed M1 polarisation, and enhanced the proportions of CD206 cells, Arg-1 expression and IL-10 levels (75.9 +- 12.8 pg/mL) in BV2 cells.	schizandrin A	10-15	arginase, liver	Mus musculus	193-198
34214019-11	2021	In vitro, Sch A treatment reduced the proportions of CD16/32+ cells, iNOS expression and IL-6 levels (25.7 +- 5.3 pg/mL) repressed M1 polarisation, and enhanced the proportions of CD206 cells, Arg-1 expression and IL-10 levels (75.9 +- 12.8 pg/mL) in BV2 cells.	schizandrin A	10-15	interleukin 10	Mus musculus	214-219
34017577-0	2021	Deoxyschizandrin treats mice with ulcerative colitis possibly via the TLR4/NF-kappaB signaling pathway.	schizandrin A	0-16	toll-like receptor 4	Mus musculus	70-74
34320092-0	2021	Retraction notice for: "Schizandrin A exerts anti-tumor effects on A375 cells by down-regulating H19" (Braz J Med Biol Res (2019) 52(10): e8385).	schizandrin A	24-37	H19 imprinted maternally expressed transcript	Homo sapiens	97-101
35614991-0	2022	Retraction Notice to: Schizandrin A Protects Human Retinal Pigment Epithelial Cell Line ARPE-19 against HG-Induced Cell Injury by Regulation of miR-145.	schizandrin A	22-35	microRNA 145	Homo sapiens	144-151
35615264-0	2022	Retraction Notice to: Schizandrin A Protects Human Retinal Pigment Epithelial Cell Line ARPE-19 against HG-Induced Cell Injury by Regulation of miR-145.	schizandrin A	22-35	microRNA 145	Homo sapiens	144-151
34017577-0	2021	Deoxyschizandrin treats mice with ulcerative colitis possibly via the TLR4/NF-kappaB signaling pathway.	schizandrin A	0-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	75-84
32076762-9	2020	The western blot and immunohistochemical assay results revealed that the toll-like receptor 4/nuclear factor kappa-B (TLR4/NF-kappaB) pathway could play a role in the anti-inflammatory functions of Sch A.	schizandrin A	198-203	toll-like receptor 4	Mus musculus	118-132
33673653-0	2021	Investigation of the Impact of CYP3A5 Polymorphism on Drug-Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling.	schizandrin A	115-128	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	31-37
33673653-2	2021	Two abundant active ingredients, schisantherin A (STA) and schisandrin A (SIA) are known to inhibit CYP3A enzymes and increase tacrolimus"s exposure.	schizandrin A	59-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-105
32354126-5	2020	In addition, SNA treatment significantly reduced the expression of muscle degradation factors such as myostatin, MAFbx (atrogin1), and muscle RING-finger protein-1 (MuRF1) and enhanced the expression of myosin heavy chain (MyHC) compared to the vehicle.	schizandrin A	13-16	F-box protein 32	Mus musculus	113-118
32871020-0	2020	Schisandrin A restrains osteoclastogenesis by inhibiting reactive oxygen species and activating Nrf2 signalling.	schizandrin A	0-13	nuclear factor, erythroid derived 2, like 2	Mus musculus	96-100
32871020-2	2020	This study aimed to prove that schisandrin A (Sch), a novel anti-oxidant compound, is able to suppress osteoclastogenesis and prevent bone loss in ovariectomized (OVX) mice by suppressing ROS via nuclear factor erythroid 2-related factor (Nrf2).	schizandrin A	31-44	nuclear factor, erythroid derived 2, like 2	Mus musculus	196-237
32871020-2	2020	This study aimed to prove that schisandrin A (Sch), a novel anti-oxidant compound, is able to suppress osteoclastogenesis and prevent bone loss in ovariectomized (OVX) mice by suppressing ROS via nuclear factor erythroid 2-related factor (Nrf2).	schizandrin A	31-44	nuclear factor, erythroid derived 2, like 2	Mus musculus	239-243
32871020-2	2020	This study aimed to prove that schisandrin A (Sch), a novel anti-oxidant compound, is able to suppress osteoclastogenesis and prevent bone loss in ovariectomized (OVX) mice by suppressing ROS via nuclear factor erythroid 2-related factor (Nrf2).	schizandrin A	46-49	nuclear factor, erythroid derived 2, like 2	Mus musculus	196-237
32871020-2	2020	This study aimed to prove that schisandrin A (Sch), a novel anti-oxidant compound, is able to suppress osteoclastogenesis and prevent bone loss in ovariectomized (OVX) mice by suppressing ROS via nuclear factor erythroid 2-related factor (Nrf2).	schizandrin A	46-49	nuclear factor, erythroid derived 2, like 2	Mus musculus	239-243
32871020-4	2020	The effects of Sch on receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced reactive oxygen species (ROS) were measured by dihydroethidium (DHE) staining in vivo and 2",7"-dichlorodihydrofluorescein diacetate (DCFH-DA) staining in vitro.	schizandrin A	15-18	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	86-91
32871020-7	2020	RESULTS: Sch suppresses RANKL-induced ROS production by regulating nuclear factor erythroid 2-related factor (Nrf2) in vitro and vivo.	schizandrin A	9-12	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	24-29
32871020-7	2020	RESULTS: Sch suppresses RANKL-induced ROS production by regulating nuclear factor erythroid 2-related factor (Nrf2) in vitro and vivo.	schizandrin A	9-12	nuclear factor, erythroid derived 2, like 2	Mus musculus	67-108
32871020-7	2020	RESULTS: Sch suppresses RANKL-induced ROS production by regulating nuclear factor erythroid 2-related factor (Nrf2) in vitro and vivo.	schizandrin A	9-12	nuclear factor, erythroid derived 2, like 2	Mus musculus	110-114
32871020-8	2020	Mechanistically, Sch enhances the expression of Nrf2 by regulating the degradation of Nrf2.	schizandrin A	17-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	48-52
32871020-8	2020	Mechanistically, Sch enhances the expression of Nrf2 by regulating the degradation of Nrf2.	schizandrin A	17-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	86-90
32871020-9	2020	Further, Sch suppresses phosphorylation of P65 and its nuclear translocation, as well as the degradation of IkappaBalpha.	schizandrin A	9-12	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	43-46
32871020-9	2020	Further, Sch suppresses phosphorylation of P65 and its nuclear translocation, as well as the degradation of IkappaBalpha.	schizandrin A	9-12	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	108-120
32871020-10	2020	Collectively, our findings reveal that Sch protects against OVX-induced bone loss by suppressing ROS via Nrf2.	schizandrin A	39-42	nuclear factor, erythroid derived 2, like 2	Mus musculus	105-109
32871020-11	2020	CONCLUSIONS: Our results showed the potential of anti-oxidant compound schisandrin A in the treatment of osteoporosis, highlighting Nrf2 as a novel promising target in osteoclast-related disease.	schizandrin A	71-84	nuclear factor, erythroid derived 2, like 2	Mus musculus	132-136
32623835-0	2020	Schizandrin A inhibits cellular phenotypes of breast cancer cells by repressing miR-155.	schizandrin A	0-13	microRNA 155	Homo sapiens	80-87
32623835-11	2020	SchA strikingly decreases miR-155.	schizandrin A	0-4	microRNA 155	Homo sapiens	26-33
32623835-12	2020	Exogenous miR-155 counteracts the inhibitory effects that SchA confers on proliferative and motional activities.	schizandrin A	58-62	microRNA 155	Homo sapiens	10-17
32623835-13	2020	Finally, SchA was observed to blunt PI3K/AKT and Wnt/beta-catenin while miR-155 mimic reverses the effects.	schizandrin A	9-13	AKT serine/threonine kinase 1	Homo sapiens	41-44
32623835-13	2020	Finally, SchA was observed to blunt PI3K/AKT and Wnt/beta-catenin while miR-155 mimic reverses the effects.	schizandrin A	9-13	catenin beta 1	Homo sapiens	53-65
32623835-14	2020	CONCLUSION: Taken together, SchA downregulates miR-155 and results in the suppression of proliferation and motility in breast cancer cells.	schizandrin A	28-32	microRNA 155	Homo sapiens	47-54
33239129-9	2020	However, the mRNA expression of liver CYP2C19 and the protein expression of liver CYP2C19 were surprisingly increased after treatment with WZ, schisandrol B and schisandrin A in rats.	schizandrin A	161-174	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	38-45
33239129-9	2020	However, the mRNA expression of liver CYP2C19 and the protein expression of liver CYP2C19 were surprisingly increased after treatment with WZ, schisandrol B and schisandrin A in rats.	schizandrin A	161-174	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	82-89
32354126-5	2020	In addition, SNA treatment significantly reduced the expression of muscle degradation factors such as myostatin, MAFbx (atrogin1), and muscle RING-finger protein-1 (MuRF1) and enhanced the expression of myosin heavy chain (MyHC) compared to the vehicle.	schizandrin A	13-16	F-box protein 32	Mus musculus	120-128
32354126-5	2020	In addition, SNA treatment significantly reduced the expression of muscle degradation factors such as myostatin, MAFbx (atrogin1), and muscle RING-finger protein-1 (MuRF1) and enhanced the expression of myosin heavy chain (MyHC) compared to the vehicle.	schizandrin A	13-16	tripartite motif-containing 63	Mus musculus	135-163
32354126-5	2020	In addition, SNA treatment significantly reduced the expression of muscle degradation factors such as myostatin, MAFbx (atrogin1), and muscle RING-finger protein-1 (MuRF1) and enhanced the expression of myosin heavy chain (MyHC) compared to the vehicle.	schizandrin A	13-16	tripartite motif-containing 63	Mus musculus	165-170
32354126-5	2020	In addition, SNA treatment significantly reduced the expression of muscle degradation factors such as myostatin, MAFbx (atrogin1), and muscle RING-finger protein-1 (MuRF1) and enhanced the expression of myosin heavy chain (MyHC) compared to the vehicle.	schizandrin A	13-16	myosin heavy chain, cardiac muscle complex	Mus musculus	203-221
32354126-5	2020	In addition, SNA treatment significantly reduced the expression of muscle degradation factors such as myostatin, MAFbx (atrogin1), and muscle RING-finger protein-1 (MuRF1) and enhanced the expression of myosin heavy chain (MyHC) compared to the vehicle.	schizandrin A	13-16	myosin heavy chain, cardiac muscle complex	Mus musculus	223-227
32354126-6	2020	In vitro studies using differentiated C2C12 myotubes also showed that SNA treatment decreased the expression of muscle degradation factors induced by dexamethasone and increased protein synthesis and expression of MyHCs by regulation of Akt/FoxO and Akt/70S6K pathways, respectively.	schizandrin A	70-73	thymoma viral proto-oncogene 1	Mus musculus	237-240
32354126-6	2020	In vitro studies using differentiated C2C12 myotubes also showed that SNA treatment decreased the expression of muscle degradation factors induced by dexamethasone and increased protein synthesis and expression of MyHCs by regulation of Akt/FoxO and Akt/70S6K pathways, respectively.	schizandrin A	70-73	thymoma viral proto-oncogene 1	Mus musculus	250-253
32057180-0	2020	MEG3 is restored by schisandrin A and represses tumor growth in choriocarcinoma cells.	schizandrin A	20-33	maternally expressed 3	Homo sapiens	0-4
32057180-4	2020	After stimulation with SchA, proliferation, apoptosis, migration, and invasion were detected by bromodeoxyuridine assay, Annexin V-fluorescein isothiocyanate/propidium iodide (Annexin V-FITC/PI) method, and a Transwell system, in JEG-3 cells transfected with short hairpin-RNA for maternally expressed 3.	schizandrin A	23-27	annexin A5	Homo sapiens	121-130
32057180-4	2020	After stimulation with SchA, proliferation, apoptosis, migration, and invasion were detected by bromodeoxyuridine assay, Annexin V-fluorescein isothiocyanate/propidium iodide (Annexin V-FITC/PI) method, and a Transwell system, in JEG-3 cells transfected with short hairpin-RNA for maternally expressed 3.	schizandrin A	23-27	annexin A5	Homo sapiens	176-185
32057180-8	2020	SchA diminished cellular viability, decreased proliferative activity, inhibited migratory and invasive behaviors, and repressed phosphorylation of regulators of phosphatidylinositol 3 kinase/protein kinase B/nuclear factor kappaB (PI3K/AKT/NF-kappaB) signaling cascade in gestational choriocarcinoma cells.	schizandrin A	0-4	protein tyrosine kinase 2 beta	Homo sapiens	191-207
32057180-8	2020	SchA diminished cellular viability, decreased proliferative activity, inhibited migratory and invasive behaviors, and repressed phosphorylation of regulators of phosphatidylinositol 3 kinase/protein kinase B/nuclear factor kappaB (PI3K/AKT/NF-kappaB) signaling cascade in gestational choriocarcinoma cells.	schizandrin A	0-4	AKT serine/threonine kinase 1	Homo sapiens	236-239
32057180-8	2020	SchA diminished cellular viability, decreased proliferative activity, inhibited migratory and invasive behaviors, and repressed phosphorylation of regulators of phosphatidylinositol 3 kinase/protein kinase B/nuclear factor kappaB (PI3K/AKT/NF-kappaB) signaling cascade in gestational choriocarcinoma cells.	schizandrin A	0-4	nuclear factor kappa B subunit 1	Homo sapiens	240-249
32057180-9	2020	MEG3 was upregulated by SchA in JEG-3 and BeWo cells.	schizandrin A	24-28	maternally expressed 3	Homo sapiens	0-4
32057180-12	2020	SchA administration repressed the growth of JEG-3 and BeWo cells by upregulating MEG3.	schizandrin A	0-4	maternally expressed 3	Homo sapiens	81-85
32057180-13	2020	Besides, SchA blocked PI3K/AKT/NF-kappaB signal cascade by elevating MEG3.	schizandrin A	9-13	AKT serine/threonine kinase 1	Homo sapiens	27-30
32057180-13	2020	Besides, SchA blocked PI3K/AKT/NF-kappaB signal cascade by elevating MEG3.	schizandrin A	9-13	nuclear factor kappa B subunit 1	Homo sapiens	31-40
32057180-13	2020	Besides, SchA blocked PI3K/AKT/NF-kappaB signal cascade by elevating MEG3.	schizandrin A	9-13	maternally expressed 3	Homo sapiens	69-73
32058027-8	2020	Our findings showed that schizandrin markedly inhibited pathological changes, pulmonary edema, MPO activity and MDA content.	schizandrin A	25-36	eosinophil peroxidase	Gallus gallus	95-98
32110802-0	2020	Schizandrin A exhibits potent anticancer activity in colorectal cancer cells by inhibiting heat shock factor 1.	schizandrin A	0-13	heat shock transcription factor 1	Homo sapiens	91-110
32110802-6	2020	In addition, Sch A could effectively inhibit the induction of HSF1 target proteins such as heat-shock protein (HSP) 70 (HSP70) and HSP27, whether in heat shock or normal temperature culture.	schizandrin A	13-18	heat shock transcription factor 1	Homo sapiens	62-66
32110802-6	2020	In addition, Sch A could effectively inhibit the induction of HSF1 target proteins such as heat-shock protein (HSP) 70 (HSP70) and HSP27, whether in heat shock or normal temperature culture.	schizandrin A	13-18	heat shock protein family A (Hsp70) member 4	Homo sapiens	91-118
32110802-6	2020	In addition, Sch A could effectively inhibit the induction of HSF1 target proteins such as heat-shock protein (HSP) 70 (HSP70) and HSP27, whether in heat shock or normal temperature culture.	schizandrin A	13-18	heat shock protein family A (Hsp70) member 4	Homo sapiens	120-125
32110802-6	2020	In addition, Sch A could effectively inhibit the induction of HSF1 target proteins such as heat-shock protein (HSP) 70 (HSP70) and HSP27, whether in heat shock or normal temperature culture.	schizandrin A	13-18	heat shock protein family B (small) member 1	Homo sapiens	131-136
31794890-0	2020	Schizandrin A Protects Human Retinal Pigment Epithelial Cell Line ARPE-19 against HG-Induced Cell Injury by Regulation of miR-145.	schizandrin A	0-13	microRNA 145	Homo sapiens	122-129
31794890-5	2020	We observed that SchA accelerated cell proliferation, prohibited apoptosis, and restrained pro-inflammatory cytokines (monocyte chemoattractant protein-1 [MCP-1], interleukin-6 [IL-6], and tumor necrosis factor alpha [TNF-alpha]) and reactive oxygen species (ROS) level in HG-stimulated cells.	schizandrin A	17-21	C-C motif chemokine ligand 2	Homo sapiens	119-153
31794890-5	2020	We observed that SchA accelerated cell proliferation, prohibited apoptosis, and restrained pro-inflammatory cytokines (monocyte chemoattractant protein-1 [MCP-1], interleukin-6 [IL-6], and tumor necrosis factor alpha [TNF-alpha]) and reactive oxygen species (ROS) level in HG-stimulated cells.	schizandrin A	17-21	C-C motif chemokine ligand 2	Homo sapiens	155-160
31794890-5	2020	We observed that SchA accelerated cell proliferation, prohibited apoptosis, and restrained pro-inflammatory cytokines (monocyte chemoattractant protein-1 [MCP-1], interleukin-6 [IL-6], and tumor necrosis factor alpha [TNF-alpha]) and reactive oxygen species (ROS) level in HG-stimulated cells.	schizandrin A	17-21	interleukin 6	Homo sapiens	163-176
31794890-5	2020	We observed that SchA accelerated cell proliferation, prohibited apoptosis, and restrained pro-inflammatory cytokines (monocyte chemoattractant protein-1 [MCP-1], interleukin-6 [IL-6], and tumor necrosis factor alpha [TNF-alpha]) and reactive oxygen species (ROS) level in HG-stimulated cells.	schizandrin A	17-21	interleukin 6	Homo sapiens	178-182
31794890-5	2020	We observed that SchA accelerated cell proliferation, prohibited apoptosis, and restrained pro-inflammatory cytokines (monocyte chemoattractant protein-1 [MCP-1], interleukin-6 [IL-6], and tumor necrosis factor alpha [TNF-alpha]) and reactive oxygen species (ROS) level in HG-stimulated cells.	schizandrin A	17-21	tumor necrosis factor	Homo sapiens	189-216
31794890-5	2020	We observed that SchA accelerated cell proliferation, prohibited apoptosis, and restrained pro-inflammatory cytokines (monocyte chemoattractant protein-1 [MCP-1], interleukin-6 [IL-6], and tumor necrosis factor alpha [TNF-alpha]) and reactive oxygen species (ROS) level in HG-stimulated cells.	schizandrin A	17-21	tumor necrosis factor	Homo sapiens	218-227
31794890-6	2020	Additionally, miR-145 expression was upregulated in HG and SchA co-treated cells, and miR-145 inhibition reversed the protective effect of SchA on HG-managed ARPE-19 cells.	schizandrin A	59-63	microRNA 145	Homo sapiens	14-21
31794890-6	2020	Additionally, miR-145 expression was upregulated in HG and SchA co-treated cells, and miR-145 inhibition reversed the protective effect of SchA on HG-managed ARPE-19 cells.	schizandrin A	139-143	microRNA 145	Homo sapiens	86-93
31794890-7	2020	Interestingly, downregulated myeloid differentiation factor 88 (MyD88) was found in HG and SchA co-treated cells, and upregulation of MyD88 was observed in miR-145 inhibitor-transfected cells.	schizandrin A	91-95	MYD88 innate immune signal transduction adaptor	Homo sapiens	29-62
31794890-7	2020	Interestingly, downregulated myeloid differentiation factor 88 (MyD88) was found in HG and SchA co-treated cells, and upregulation of MyD88 was observed in miR-145 inhibitor-transfected cells.	schizandrin A	91-95	MYD88 innate immune signal transduction adaptor	Homo sapiens	64-69
31794890-8	2020	Additionally, SchA hindered nuclear factor kappaB (NF-kappaB) and p38 mitogen-activated protein kinase (p38MAPK) signaling pathways in HG-treated ARPE-19 cells.	schizandrin A	14-18	nuclear factor kappa B subunit 1	Homo sapiens	43-49
31794890-8	2020	Additionally, SchA hindered nuclear factor kappaB (NF-kappaB) and p38 mitogen-activated protein kinase (p38MAPK) signaling pathways in HG-treated ARPE-19 cells.	schizandrin A	14-18	nuclear factor kappa B subunit 1	Homo sapiens	51-60
31794890-8	2020	Additionally, SchA hindered nuclear factor kappaB (NF-kappaB) and p38 mitogen-activated protein kinase (p38MAPK) signaling pathways in HG-treated ARPE-19 cells.	schizandrin A	14-18	mitogen-activated protein kinase 14	Homo sapiens	66-102
31794890-8	2020	Additionally, SchA hindered nuclear factor kappaB (NF-kappaB) and p38 mitogen-activated protein kinase (p38MAPK) signaling pathways in HG-treated ARPE-19 cells.	schizandrin A	14-18	mitogen-activated protein kinase 14	Homo sapiens	104-111
31794890-9	2020	The findings validated that SchA could protect ARPE-19 cells from HG-induced cell injury by regulation of miR-145.	schizandrin A	28-32	microRNA 145	Homo sapiens	106-113
32274105-8	2020	Also, Sch A downregulated the expression of IL-8 and upregulated the expression of HO-1 mRNA in lung epithelial cells and cell supernatants, and resulted in the downregulation of the protein expression level of phosphorylated nuclear factor-kappaB.	schizandrin A	6-11	C-X-C motif chemokine ligand 8	Homo sapiens	44-48
32274105-8	2020	Also, Sch A downregulated the expression of IL-8 and upregulated the expression of HO-1 mRNA in lung epithelial cells and cell supernatants, and resulted in the downregulation of the protein expression level of phosphorylated nuclear factor-kappaB.	schizandrin A	6-11	heme oxygenase 1	Homo sapiens	83-87
32058027-9	2020	Moreover, schizandrin markedly reduced the levels of TNF-alpha, IL-1beta, IL-6 and IL-8 in lung tissue.	schizandrin A	10-21	lipopolysaccharide induced TNF factor	Gallus gallus	53-62
32058027-9	2020	Moreover, schizandrin markedly reduced the levels of TNF-alpha, IL-1beta, IL-6 and IL-8 in lung tissue.	schizandrin A	10-21	interleukin 1, beta	Gallus gallus	64-72
32058027-9	2020	Moreover, schizandrin markedly reduced the levels of TNF-alpha, IL-1beta, IL-6 and IL-8 in lung tissue.	schizandrin A	10-21	interleukin 6	Gallus gallus	74-78
32058027-9	2020	Moreover, schizandrin markedly reduced the levels of TNF-alpha, IL-1beta, IL-6 and IL-8 in lung tissue.	schizandrin A	10-21	interleukin 8-like 2	Gallus gallus	83-87
31767544-0	2020	Schisandrin A protects against lipopolysaccharide-induced mastitis through activating Nrf2 signaling pathway and inducing autophagy.	schizandrin A	0-13	nuclear factor, erythroid derived 2, like 2	Mus musculus	86-90
31767544-5	2020	Sch A also decreased the levels of pro-inflammatory mediators and activated nuclear factor-E2 associated factor 2 (Nrf2) signaling pathway in mouse mammary epithelial cells (mMECs).	schizandrin A	0-5	nuclear factor, erythroid derived 2, like 2	Mus musculus	76-113
31767544-5	2020	Sch A also decreased the levels of pro-inflammatory mediators and activated nuclear factor-E2 associated factor 2 (Nrf2) signaling pathway in mouse mammary epithelial cells (mMECs).	schizandrin A	0-5	nuclear factor, erythroid derived 2, like 2	Mus musculus	115-119
31767544-6	2020	The Nrf2 inhibitor partially abrogated the downregulation of Sch A on LPS-induced inflammatory response.	schizandrin A	61-66	nuclear factor, erythroid derived 2, like 2	Mus musculus	4-8
31767544-8	2020	Sch A also restrained LPS-induced phosphorylation of mammalian target of rapamycin (mTOR) and activated AMP-activated protein kinase (AMPK) and unc-51 like kinase 1 (ULK1).	schizandrin A	0-5	mechanistic target of rapamycin kinase	Homo sapiens	53-82
31767544-8	2020	Sch A also restrained LPS-induced phosphorylation of mammalian target of rapamycin (mTOR) and activated AMP-activated protein kinase (AMPK) and unc-51 like kinase 1 (ULK1).	schizandrin A	0-5	mechanistic target of rapamycin kinase	Homo sapiens	84-88
31767544-8	2020	Sch A also restrained LPS-induced phosphorylation of mammalian target of rapamycin (mTOR) and activated AMP-activated protein kinase (AMPK) and unc-51 like kinase 1 (ULK1).	schizandrin A	0-5	unc-51 like autophagy activating kinase 1	Homo sapiens	144-164
31767544-8	2020	Sch A also restrained LPS-induced phosphorylation of mammalian target of rapamycin (mTOR) and activated AMP-activated protein kinase (AMPK) and unc-51 like kinase 1 (ULK1).	schizandrin A	0-5	unc-51 like autophagy activating kinase 1	Homo sapiens	166-170
31767544-9	2020	In summary, these results suggest that Sch A exerts protective effects in LPS-induced mastitis models by activating Nrf2 signaling pathway and inducing autophagy and the autophagy is initiated by suppressing mTOR signaling pathway and activating AMPK-ULK1 signaling pathway.	schizandrin A	39-44	nuclear factor, erythroid derived 2, like 2	Mus musculus	116-120
31767544-9	2020	In summary, these results suggest that Sch A exerts protective effects in LPS-induced mastitis models by activating Nrf2 signaling pathway and inducing autophagy and the autophagy is initiated by suppressing mTOR signaling pathway and activating AMPK-ULK1 signaling pathway.	schizandrin A	39-44	mechanistic target of rapamycin kinase	Mus musculus	208-212
31767544-9	2020	In summary, these results suggest that Sch A exerts protective effects in LPS-induced mastitis models by activating Nrf2 signaling pathway and inducing autophagy and the autophagy is initiated by suppressing mTOR signaling pathway and activating AMPK-ULK1 signaling pathway.	schizandrin A	39-44	unc-51 like kinase 1	Mus musculus	246-255
31552591-4	2019	Pre-treatment with Sch A significantly decreased the levels of the inflammatory mediators IL-6, IL-1beta, and TNF-alpha and markedly improved antioxidant defences by inhibiting the activity of MDA and increasing that of SOD.	schizandrin A	19-24	interleukin 6	Mus musculus	90-94
31844123-9	2019	In addition, Sch A decreased the DON-induced cyclooxygenase-2 expression and prostaglandin E2 production and pro-inflammatory cytokine interleukin 8 expression and secretion.	schizandrin A	13-18	C-X-C motif chemokine ligand 8	Homo sapiens	135-148
31871476-6	2019	After the intervention of deoxyschisandrin, colon mucosa BDNF protein expression in IBD mice decreased, indicating that deoxyschisandrin could decrease mouse intestinal sensitivity by reducing colon mucosa BDNF expression.	schizandrin A	26-42	brain derived neurotrophic factor	Mus musculus	57-61
31871476-6	2019	After the intervention of deoxyschisandrin, colon mucosa BDNF protein expression in IBD mice decreased, indicating that deoxyschisandrin could decrease mouse intestinal sensitivity by reducing colon mucosa BDNF expression.	schizandrin A	26-42	brain derived neurotrophic factor	Mus musculus	206-210
31871476-6	2019	After the intervention of deoxyschisandrin, colon mucosa BDNF protein expression in IBD mice decreased, indicating that deoxyschisandrin could decrease mouse intestinal sensitivity by reducing colon mucosa BDNF expression.	schizandrin A	120-136	brain derived neurotrophic factor	Mus musculus	57-61
31871476-6	2019	After the intervention of deoxyschisandrin, colon mucosa BDNF protein expression in IBD mice decreased, indicating that deoxyschisandrin could decrease mouse intestinal sensitivity by reducing colon mucosa BDNF expression.	schizandrin A	120-136	brain derived neurotrophic factor	Mus musculus	206-210
31871476-7	2019	In conclusion, deoxyschisandrin possessed antidiarrheal effects and visceral hypersensitivity inhibitory effects in the mice with IBD induced by TNBS, which was related to the reduction in BDNF expression in the colon.	schizandrin A	15-31	brain derived neurotrophic factor	Mus musculus	189-193
31844123-9	2019	In addition, Sch A decreased the DON-induced cyclooxygenase-2 expression and prostaglandin E2 production and pro-inflammatory cytokine interleukin 8 expression and secretion.	schizandrin A	13-18	prostaglandin-endoperoxide synthase 2	Homo sapiens	45-61
31552591-4	2019	Pre-treatment with Sch A significantly decreased the levels of the inflammatory mediators IL-6, IL-1beta, and TNF-alpha and markedly improved antioxidant defences by inhibiting the activity of MDA and increasing that of SOD.	schizandrin A	19-24	interleukin 1 alpha	Mus musculus	96-104
31552591-4	2019	Pre-treatment with Sch A significantly decreased the levels of the inflammatory mediators IL-6, IL-1beta, and TNF-alpha and markedly improved antioxidant defences by inhibiting the activity of MDA and increasing that of SOD.	schizandrin A	19-24	tumor necrosis factor	Mus musculus	110-119
31552591-5	2019	Furthermore, Sch A activated expression of the autophagy-related proteins LC3-II, beclin1, parkin, and PINK1 and increased mTOR expression.	schizandrin A	13-18	beclin 1, autophagy related	Mus musculus	82-89
31552591-5	2019	Furthermore, Sch A activated expression of the autophagy-related proteins LC3-II, beclin1, parkin, and PINK1 and increased mTOR expression.	schizandrin A	13-18	PTEN induced putative kinase 1	Mus musculus	103-108
31552591-5	2019	Furthermore, Sch A activated expression of the autophagy-related proteins LC3-II, beclin1, parkin, and PINK1 and increased mTOR expression.	schizandrin A	13-18	mechanistic target of rapamycin kinase	Mus musculus	123-127
29405807-0	2019	Interaction of deoxyschizandrin and schizandrin B with liver uptake transporters OATP1B1 and OATP1B3.	schizandrin A	15-31	solute carrier organic anion transporter family member 1B1	Homo sapiens	81-88
31618367-0	2019	Schizandrin A exerts anti-tumor effects on A375 cells by down-regulating H19.	schizandrin A	0-13	H19 imprinted maternally expressed transcript	Homo sapiens	73-76
31618367-10	2019	Furthermore, SchA inhibited cell proliferation and cyclin D1 expression.	schizandrin A	13-17	cyclin D1	Homo sapiens	51-60
31618367-11	2019	SchA increased cell apoptosis along with the up-regulation of pro-apoptotic proteins (cleaved-caspase-3, cleaved-caspase-9, and Bax) and the down-regulation of anti-apoptotic protein (Bcl-2).	schizandrin A	0-4	caspase 9	Homo sapiens	113-122
31618367-11	2019	SchA increased cell apoptosis along with the up-regulation of pro-apoptotic proteins (cleaved-caspase-3, cleaved-caspase-9, and Bax) and the down-regulation of anti-apoptotic protein (Bcl-2).	schizandrin A	0-4	BCL2 associated X, apoptosis regulator	Homo sapiens	128-131
31618367-11	2019	SchA increased cell apoptosis along with the up-regulation of pro-apoptotic proteins (cleaved-caspase-3, cleaved-caspase-9, and Bax) and the down-regulation of anti-apoptotic protein (Bcl-2).	schizandrin A	0-4	BCL2 apoptosis regulator	Homo sapiens	184-189
31618367-12	2019	Besides, SchA decreased migration and down-regulated matrix metalloproteinases (MMP)-2 and MMP-9.	schizandrin A	9-13	matrix metallopeptidase 2	Homo sapiens	53-86
31618367-12	2019	Besides, SchA decreased migration and down-regulated matrix metalloproteinases (MMP)-2 and MMP-9.	schizandrin A	9-13	matrix metallopeptidase 9	Homo sapiens	91-96
31618367-14	2019	Overexpression of H19 blockaded the inhibitory effects of SchA on A375 cells.	schizandrin A	58-62	H19 imprinted maternally expressed transcript	Homo sapiens	18-21
31618367-15	2019	SchA decreased the phosphorylation of PI3K and AKT while H19 overexpression promoted the phosphorylation of PI3K and AKT.	schizandrin A	0-4	AKT serine/threonine kinase 1	Homo sapiens	47-50
31618367-16	2019	SchA inhibited A375 cell growth, migration, and the PI3K/AKT pathway through down-regulating H19.	schizandrin A	0-4	AKT serine/threonine kinase 1	Homo sapiens	57-60
31618367-16	2019	SchA inhibited A375 cell growth, migration, and the PI3K/AKT pathway through down-regulating H19.	schizandrin A	0-4	H19 imprinted maternally expressed transcript	Homo sapiens	93-96
31597329-0	2019	Schizandrin Protects against OGD/R-Induced Neuronal Injury by Suppressing Autophagy: Involvement of the AMPK/mTOR Pathway.	schizandrin A	0-11	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	104-108
31597329-0	2019	Schizandrin Protects against OGD/R-Induced Neuronal Injury by Suppressing Autophagy: Involvement of the AMPK/mTOR Pathway.	schizandrin A	0-11	mechanistic target of rapamycin kinase	Rattus norvegicus	109-113
31597329-3	2019	This study aimed to explore whether the neuroprotective mechanisms of SA were linked to its regulation of AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)/autophagy pathway in vivo and in vitro.	schizandrin A	70-72	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	136-140
31597329-3	2019	This study aimed to explore whether the neuroprotective mechanisms of SA were linked to its regulation of AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)/autophagy pathway in vivo and in vitro.	schizandrin A	70-72	mechanistic target of rapamycin kinase	Homo sapiens	142-171
31597329-3	2019	This study aimed to explore whether the neuroprotective mechanisms of SA were linked to its regulation of AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)/autophagy pathway in vivo and in vitro.	schizandrin A	70-72	mechanistic target of rapamycin kinase	Homo sapiens	173-177
31597329-5	2019	The results of immunoblotting and confocal microscope showed that SA decreased autophagy in OGD/R-injured PC12 cells, which was reflected by the decreased Beclin-1 and LC3-II expression, autophagy flux level, and LC3 puncta formation.	schizandrin A	66-68	beclin 1	Rattus norvegicus	155-163
31597329-7	2019	The results of Western blotting showed that SA markedly decreased the phosphorylation of AMPK (p-AMPK), whereas the phosphor-mTOR (p-mTOR) levels increased in the presence of OGD/R insult.	schizandrin A	44-46	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	89-93
31597329-7	2019	The results of Western blotting showed that SA markedly decreased the phosphorylation of AMPK (p-AMPK), whereas the phosphor-mTOR (p-mTOR) levels increased in the presence of OGD/R insult.	schizandrin A	44-46	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	95-101
31597329-8	2019	Furthermore, pretreatment with the AMPK inducer AICAR partially reversed the protective effects and autophagy inhibition of SA.	schizandrin A	124-126	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	35-39
31597329-9	2019	However, AMPK inhibitor Compound C pretreatment further promoted the inhibition of SA on autophagy induction and cell damage induced by OGD/R.	schizandrin A	83-85	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	9-13
31597329-10	2019	Taken together, these findings demonstrate that SA protects against OGD/R insult by inhibiting autophagy through the regulation of the AMPK-mTOR pathway and that SA may have therapeutic value for protecting neurons from cerebral ischemia.	schizandrin A	48-50	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	135-139
31597329-10	2019	Taken together, these findings demonstrate that SA protects against OGD/R insult by inhibiting autophagy through the regulation of the AMPK-mTOR pathway and that SA may have therapeutic value for protecting neurons from cerebral ischemia.	schizandrin A	48-50	mechanistic target of rapamycin kinase	Rattus norvegicus	140-144
30486721-4	2019	This study aims to evaluate the inhibition of carboxylesterases (CESs) by the major ingredients isolated from Schisandra chinensis, including Anwuligan, Schisandrol B, Schisanhenol, deoxyschizandrin, and Schisandrin B.	schizandrin A	182-198	carboxylesterase 1	Homo sapiens	46-63
31028739-0	2019	Schizandrin A enhances the efficacy of gefitinib by suppressing IKKbeta/NF-kappaB signaling in non-small cell lung cancer.	schizandrin A	0-13	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	64-71
31028739-0	2019	Schizandrin A enhances the efficacy of gefitinib by suppressing IKKbeta/NF-kappaB signaling in non-small cell lung cancer.	schizandrin A	0-13	nuclear factor kappa B subunit 1	Homo sapiens	72-81
31028739-5	2019	Sch A effectively suppressed the phosphorylation of IKKbeta and IkappaBalpha, as well as the nuclear translocation of NF-kappaB p65, and showed high and selective affinity for IKKbeta in surface plasmon resonance (SPR) experiments, indicating that Sch A was a selective IKKbeta inhibitor.	schizandrin A	0-5	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	52-59
31028739-5	2019	Sch A effectively suppressed the phosphorylation of IKKbeta and IkappaBalpha, as well as the nuclear translocation of NF-kappaB p65, and showed high and selective affinity for IKKbeta in surface plasmon resonance (SPR) experiments, indicating that Sch A was a selective IKKbeta inhibitor.	schizandrin A	0-5	NFKB inhibitor alpha	Homo sapiens	64-76
31028739-5	2019	Sch A effectively suppressed the phosphorylation of IKKbeta and IkappaBalpha, as well as the nuclear translocation of NF-kappaB p65, and showed high and selective affinity for IKKbeta in surface plasmon resonance (SPR) experiments, indicating that Sch A was a selective IKKbeta inhibitor.	schizandrin A	0-5	RELA proto-oncogene, NF-kB subunit	Homo sapiens	118-131
31028739-5	2019	Sch A effectively suppressed the phosphorylation of IKKbeta and IkappaBalpha, as well as the nuclear translocation of NF-kappaB p65, and showed high and selective affinity for IKKbeta in surface plasmon resonance (SPR) experiments, indicating that Sch A was a selective IKKbeta inhibitor.	schizandrin A	0-5	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	176-183
31028739-5	2019	Sch A effectively suppressed the phosphorylation of IKKbeta and IkappaBalpha, as well as the nuclear translocation of NF-kappaB p65, and showed high and selective affinity for IKKbeta in surface plasmon resonance (SPR) experiments, indicating that Sch A was a selective IKKbeta inhibitor.	schizandrin A	0-5	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	176-183
31028739-6	2019	Molecular modeling between IKKbeta and Sch A suggested that Sch A formed key hydrophobic interactions with IKKbeta, which may contribute to its potent IKKbeta inhibitory effect.	schizandrin A	39-44	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	107-114
31028739-6	2019	Molecular modeling between IKKbeta and Sch A suggested that Sch A formed key hydrophobic interactions with IKKbeta, which may contribute to its potent IKKbeta inhibitory effect.	schizandrin A	39-44	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	107-114
31028739-6	2019	Molecular modeling between IKKbeta and Sch A suggested that Sch A formed key hydrophobic interactions with IKKbeta, which may contribute to its potent IKKbeta inhibitory effect.	schizandrin A	60-65	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	27-34
31028739-6	2019	Molecular modeling between IKKbeta and Sch A suggested that Sch A formed key hydrophobic interactions with IKKbeta, which may contribute to its potent IKKbeta inhibitory effect.	schizandrin A	60-65	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	107-114
31028739-6	2019	Molecular modeling between IKKbeta and Sch A suggested that Sch A formed key hydrophobic interactions with IKKbeta, which may contribute to its potent IKKbeta inhibitory effect.	schizandrin A	60-65	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	107-114
31028739-7	2019	These findings suggest a novel approach to improve poor clinical outcomes in EGFR TKIs therapy, by combining it with Sch A.	schizandrin A	117-122	epidermal growth factor receptor	Homo sapiens	77-81
29405807-0	2019	Interaction of deoxyschizandrin and schizandrin B with liver uptake transporters OATP1B1 and OATP1B3.	schizandrin A	15-31	solute carrier organic anion transporter family member 1B3	Homo sapiens	93-100
29405807-5	2019	Deoxyschizandrin exhibited a high affinity for OATP1B1 with Km of 17.61 +- 0.43 muM but a low affinity for OATP1B3.	schizandrin A	0-16	solute carrier organic anion transporter family member 1B1	Homo sapiens	47-54
29405807-5	2019	Deoxyschizandrin exhibited a high affinity for OATP1B1 with Km of 17.61 +- 0.43 muM but a low affinity for OATP1B3.	schizandrin A	0-16	solute carrier organic anion transporter family member 1B3	Homo sapiens	107-114
29405807-8	2019	Atorvastatin and rifampicin could inhibit the uptake of deoxyschizandrin and schizandrin B mediated by OATP1B1.	schizandrin A	56-72	solute carrier organic anion transporter family member 1B1	Homo sapiens	103-110
29405807-10	2019	Intriguingly, both deoxyschizandrin and schizandrin B significantly promoted the uptake of atorvastatin (with EC50 of 50.58 +- 8.08 and 24.70 +- 5.82 microM, respectively) and rosuvastatin (with EC50 of 13.46 +- 2.70 and 8.99 +- 4.73 microM, respectively) mediated by OATP1B1.	schizandrin A	19-35	solute carrier organic anion transporter family member 1B1	Homo sapiens	268-275
29405807-11	2019	Deoxyschizandrin could markedly promote the uptake of fluvastatin but inhibit the uptake of sodium taurocholate (TCNa) mediated by OATP1B1.	schizandrin A	0-16	solute carrier organic anion transporter family member 1B1	Homo sapiens	131-138
29405807-13	2019	The promotion on hepatic uptake of statins mediated by OATP1B1 might lead to enhanced efficacy of cholesterol lowering and reduced risk of myopathy for hyperlipidemia patients when given statins together with deoxyschizandrin or schizandrin B.	schizandrin A	209-225	solute carrier organic anion transporter family member 1B1	Homo sapiens	55-62
28945011-1	2018	Schisantherin A and schisandrin A, the most abundant active ingredients of Wuzhi capsule, are known to inhibit tacrolimus metabolism by inhibiting CYP3A4/5.	schizandrin A	20-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	147-153
30761007-0	2019	Schisandrin A Inhibits the IL-1beta-Induced Inflammation and Cartilage Degradation via Suppression of MAPK and NF-kappaB Signal Pathways in Rat Chondrocytes.	schizandrin A	0-13	interleukin 1 beta	Rattus norvegicus	27-35
30761007-11	2019	Our results revealed that Schisandrin A could suppress the IL-1beta-induced production of NO and PGE2 in rat chondrocytes.	schizandrin A	26-39	interleukin 1 beta	Rattus norvegicus	59-67
30761007-12	2019	Consistent with these findings, the upregulation of iNOS and Cox2 could also been decreased by Schisandrin A.	schizandrin A	95-108	nitric oxide synthase 2	Rattus norvegicus	52-56
30761007-12	2019	Consistent with these findings, the upregulation of iNOS and Cox2 could also been decreased by Schisandrin A.	schizandrin A	95-108	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	61-65
30761007-13	2019	Additionally, Schisandrin A could inhibit IL-1beta-induced cartilage matrix catabolic enzymes including MMPs and ADAMTS5.	schizandrin A	14-27	interleukin 1 beta	Rattus norvegicus	42-50
30761007-13	2019	Additionally, Schisandrin A could inhibit IL-1beta-induced cartilage matrix catabolic enzymes including MMPs and ADAMTS5.	schizandrin A	14-27	matrix metallopeptidase 1	Rattus norvegicus	104-108
30761007-13	2019	Additionally, Schisandrin A could inhibit IL-1beta-induced cartilage matrix catabolic enzymes including MMPs and ADAMTS5.	schizandrin A	14-27	ADAM metallopeptidase with thrombospondin type 1 motif, 5	Rattus norvegicus	113-120
30761007-14	2019	Moreover, the IL-1beta-induced downregulation of Collagen II, aggrecan, and Sox9 could be ameliorated by Schisandrin A.	schizandrin A	105-118	interleukin 1 beta	Rattus norvegicus	14-22
30761007-14	2019	Moreover, the IL-1beta-induced downregulation of Collagen II, aggrecan, and Sox9 could be ameliorated by Schisandrin A.	schizandrin A	105-118	SRY-box transcription factor 9	Rattus norvegicus	76-80
30761007-17	2019	In conclusion, this study elucidates that Schisandrin A inhibits the IL-1beta-induced inflammation and cartilage degradation via suppression of MAPK and NF-kappaB signal pathways, indicating its potential role in OA therapy.	schizandrin A	42-55	interleukin 1 beta	Rattus norvegicus	69-77
30787979-0	2019	Schizandrin A protects against cerebral ischemia-reperfusion injury by suppressing inflammation and oxidative stress and regulating the AMPK/Nrf2 pathway regulation.	schizandrin A	0-13	NFE2 like bZIP transcription factor 2	Homo sapiens	141-145
30787979-8	2019	Knockdown of Nrf2 by siRNA inhibited the neuroprotective effects of Sch A.	schizandrin A	68-73	NFE2 like bZIP transcription factor 2	Homo sapiens	13-17
30787979-10	2019	Activation of the Nrf2 pathway as well as the protective effects of Sch A in an oxygen and glucose deprivation-induced injury model was abolished by AMPK knockdown.	schizandrin A	68-73	NFE2 like bZIP transcription factor 2	Homo sapiens	18-22
30909188-0	2019	Schizandrin A inhibits proliferation, migration and invasion of thyroid cancer cell line TPC-1 by down regulation of microRNA-429.	schizandrin A	0-13	two pore segment channel 1	Homo sapiens	89-94
30119261-7	2018	In addition, schisandrin A prevented the release of H2O2-induced cytochrome c into the cytoplasm presumably by inhibiting the loss of mitochondrial membrane potential and the changes in the Bcl-2 family protein expression by H2O2.	schizandrin A	13-26	B cell leukemia/lymphoma 2	Mus musculus	190-195
30119261-8	2018	Furthermore, the blocking of H2O2-induced apoptosis by schisandrin A was associated with the inhibition of poly (ADP-ribose) polymerase degradation by the inactivation of caspase-3.	schizandrin A	55-68	caspase 3	Mus musculus	171-180
29359345-5	2018	Competitive binding assay showed piperine, praeruptorin A, and schizandrin A acting on MrgprX2 and cinobufagin and osthole act on the IgE receptor.	schizandrin A	63-76	MAS related GPR family member X2	Rattus norvegicus	87-94
28945011-3	2018	Firstly, the inhibition mechanism of schisantherin A and schisandrin A on CYP3A4/5 was investigated.	schizandrin A	57-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
29181822-0	2018	Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.	schizandrin A	0-13	RELA proto-oncogene, NF-kB subunit	Homo sapiens	96-99
29331856-0	2018	Schizandrin A enhances chemosensitivity of colon carcinoma cells to 5-fluorouracil through up-regulation of miR-195.	schizandrin A	0-13	microRNA 195	Homo sapiens	108-115
29181822-10	2018	In addition, Sch A enhanced DOX-induced cleavage of Caspase-9 and PARP levels by increasing intracellular DOX accumulation and inhibiting P-gp function.	schizandrin A	13-18	ATP binding cassette subfamily B member 1	Homo sapiens	138-142
29181822-0	2018	Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.	schizandrin A	0-13	signal transducer and activator of transcription 3	Homo sapiens	104-109
29181822-12	2018	Besides, Sch A showed inhibitory effect on P-gp transcriptional activity.	schizandrin A	9-14	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
29181822-10	2018	In addition, Sch A enhanced DOX-induced cleavage of Caspase-9 and PARP levels by increasing intracellular DOX accumulation and inhibiting P-gp function.	schizandrin A	13-18	caspase 9	Homo sapiens	52-61
29181822-10	2018	In addition, Sch A enhanced DOX-induced cleavage of Caspase-9 and PARP levels by increasing intracellular DOX accumulation and inhibiting P-gp function.	schizandrin A	13-18	collagen type XI alpha 2 chain	Homo sapiens	66-70
29115385-0	2018	Schisandrin A suppresses lipopolysaccharide-induced inflammation and oxidative stress in RAW 264.7 macrophages by suppressing the NF-kappaB, MAPKs and PI3K/Akt pathways and activating Nrf2/HO-1 signaling.	schizandrin A	0-13	thymoma viral proto-oncogene 1	Mus musculus	156-159
29342940-6	2018	Interestingly, increased production of reactive oxygen species and decreased activation of Akt were observed in A2780 cells treated with deoxyschizandrin, and the antioxidant compromised the deoxyschizandrin-induced cell growth inhibition and Akt inactivation.	schizandrin A	137-153	AKT serine/threonine kinase 1	Homo sapiens	91-94
29342940-6	2018	Interestingly, increased production of reactive oxygen species and decreased activation of Akt were observed in A2780 cells treated with deoxyschizandrin, and the antioxidant compromised the deoxyschizandrin-induced cell growth inhibition and Akt inactivation.	schizandrin A	137-153	AKT serine/threonine kinase 1	Homo sapiens	243-246
29342940-6	2018	Interestingly, increased production of reactive oxygen species and decreased activation of Akt were observed in A2780 cells treated with deoxyschizandrin, and the antioxidant compromised the deoxyschizandrin-induced cell growth inhibition and Akt inactivation.	schizandrin A	191-207	AKT serine/threonine kinase 1	Homo sapiens	91-94
29342940-7	2018	Moreover, deoxyschizandrin-induced cell growth inhibition was markedly suppressed by Akt overexpression.	schizandrin A	10-26	AKT serine/threonine kinase 1	Homo sapiens	85-88
29342940-9	2018	Moreover, expression and production of the tumour-promoting factors MMP-9, RANTES, and VEGF, which are highly enhanced in TAMs, was significantly suppressed by deoxyschizandrin treatment.	schizandrin A	160-176	matrix metallopeptidase 9	Homo sapiens	68-73
29342940-9	2018	Moreover, expression and production of the tumour-promoting factors MMP-9, RANTES, and VEGF, which are highly enhanced in TAMs, was significantly suppressed by deoxyschizandrin treatment.	schizandrin A	160-176	C-C motif chemokine ligand 5	Homo sapiens	75-81
29342940-9	2018	Moreover, expression and production of the tumour-promoting factors MMP-9, RANTES, and VEGF, which are highly enhanced in TAMs, was significantly suppressed by deoxyschizandrin treatment.	schizandrin A	160-176	vascular endothelial growth factor A	Homo sapiens	87-91
29115385-0	2018	Schisandrin A suppresses lipopolysaccharide-induced inflammation and oxidative stress in RAW 264.7 macrophages by suppressing the NF-kappaB, MAPKs and PI3K/Akt pathways and activating Nrf2/HO-1 signaling.	schizandrin A	0-13	nuclear factor, erythroid derived 2, like 2	Mus musculus	184-188
29115385-0	2018	Schisandrin A suppresses lipopolysaccharide-induced inflammation and oxidative stress in RAW 264.7 macrophages by suppressing the NF-kappaB, MAPKs and PI3K/Akt pathways and activating Nrf2/HO-1 signaling.	schizandrin A	0-13	heme oxygenase 1	Mus musculus	189-193
29115385-3	2018	In the present study, schisandrin A significantly suppressed the lipopolysaccharide (LPS)-induced production of the key pro-inflammatory mediators nitric oxide (NO) and prostaglandin E2 by suppressing the expression of inducible NO synthase and cyclooxygenase-2 at the mRNA and protein levels in RAW 264.7 macrophages.	schizandrin A	22-35	nitric oxide synthase 2, inducible	Mus musculus	219-240
29115385-3	2018	In the present study, schisandrin A significantly suppressed the lipopolysaccharide (LPS)-induced production of the key pro-inflammatory mediators nitric oxide (NO) and prostaglandin E2 by suppressing the expression of inducible NO synthase and cyclooxygenase-2 at the mRNA and protein levels in RAW 264.7 macrophages.	schizandrin A	22-35	prostaglandin-endoperoxide synthase 2	Mus musculus	245-261
29115385-4	2018	Furthermore, schisandrin A was demonstrated to reduce the LPS-induced secretion of pro-inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-1beta; this was accompanied by a simultaneous decrease in the respective mRNA and protein levels in the macrophages.	schizandrin A	13-26	tumor necrosis factor	Mus musculus	121-148
29115385-4	2018	Furthermore, schisandrin A was demonstrated to reduce the LPS-induced secretion of pro-inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-1beta; this was accompanied by a simultaneous decrease in the respective mRNA and protein levels in the macrophages.	schizandrin A	13-26	interleukin 1 beta	Mus musculus	153-170
29115385-7	2018	These results suggested that schisandrin A has a protective effect against LPS-induced inflammatory and oxidative responses in RAW 264.7 cells by inhibiting the NF-kappaB, MAPK and PI3K/Akt pathways; these effects are mediated, at least in part, by the activation of the Nrf2/HO-1 pathway.	schizandrin A	29-42	thymoma viral proto-oncogene 1	Mus musculus	186-189
29115385-7	2018	These results suggested that schisandrin A has a protective effect against LPS-induced inflammatory and oxidative responses in RAW 264.7 cells by inhibiting the NF-kappaB, MAPK and PI3K/Akt pathways; these effects are mediated, at least in part, by the activation of the Nrf2/HO-1 pathway.	schizandrin A	29-42	nuclear factor, erythroid derived 2, like 2	Mus musculus	271-275
29115385-7	2018	These results suggested that schisandrin A has a protective effect against LPS-induced inflammatory and oxidative responses in RAW 264.7 cells by inhibiting the NF-kappaB, MAPK and PI3K/Akt pathways; these effects are mediated, at least in part, by the activation of the Nrf2/HO-1 pathway.	schizandrin A	29-42	heme oxygenase 1	Mus musculus	276-280
29911779-0	2017	[Inhibitory effect and mechanism of deoxyschizandrin on NLRP3 inflammasome].	schizandrin A	36-52	NLR family pyrin domain containing 3	Homo sapiens	56-61
28604846-9	2017	Schisandrin A (Sch A) and schisandrin B (Sch B) were demonstrated to be the active components of YXSC by attenuating endothelin-1 (ET-1)-induced contraction dysfunction, brain natriuretic peptide (BNP) content elevation, and the morphological changes of hiPS-CMs.	schizandrin A	0-13	endothelin 1	Homo sapiens	117-129
28604846-9	2017	Schisandrin A (Sch A) and schisandrin B (Sch B) were demonstrated to be the active components of YXSC by attenuating endothelin-1 (ET-1)-induced contraction dysfunction, brain natriuretic peptide (BNP) content elevation, and the morphological changes of hiPS-CMs.	schizandrin A	0-13	natriuretic peptide B	Homo sapiens	170-195
28604846-9	2017	Schisandrin A (Sch A) and schisandrin B (Sch B) were demonstrated to be the active components of YXSC by attenuating endothelin-1 (ET-1)-induced contraction dysfunction, brain natriuretic peptide (BNP) content elevation, and the morphological changes of hiPS-CMs.	schizandrin A	0-13	natriuretic peptide B	Homo sapiens	197-200
28604846-9	2017	Schisandrin A (Sch A) and schisandrin B (Sch B) were demonstrated to be the active components of YXSC by attenuating endothelin-1 (ET-1)-induced contraction dysfunction, brain natriuretic peptide (BNP) content elevation, and the morphological changes of hiPS-CMs.	schizandrin A	15-20	endothelin 1	Homo sapiens	117-129
29911779-1	2017	This study was conducted to investigate the inhibitory effect and the molecular mechanism of deoxyschizandrin on the activity of NLRP3 (NOD-like receptor family, pyrin domain containing 3) inflammasome.	schizandrin A	93-109	NLR family pyrin domain containing 3	Homo sapiens	129-134
29911779-4	2017	The expression of IL-1beta, caspase-1 in the supernatant and the expression of pro-caspase-1, pro-IL-1beta, ASC, NLRP3 in cell was detected by Western blot for the inhibitory effect of deoxyschizandrin (25, 50, 100 and 200 mumol L(-1)) on the activity of NLRP3 inflammasome.	schizandrin A	185-201	interleukin 1 beta	Homo sapiens	94-106
25975095-4	2015	In this study, we aimed to investigate the effect of schisandrin A, schisandrin B and tanshinone IIA, which were extracted from medicinal plants, on OATP1B1 activity.	schizandrin A	53-66	solute carrier organic anion transporter family member 1B1	Homo sapiens	149-156
29911779-7	2017	Deoxyschizandrin (25, 50, 100, and 200 mumol L(-1)) could inhibit the activation of NLRP3 inflammasome caused by nigericin and ATP, and inhibit the secretion of IL-1beta, which was associated with inhibiting the cleavage of pro-caspase-1.	schizandrin A	0-16	NLR family pyrin domain containing 3	Homo sapiens	84-89
29911779-7	2017	Deoxyschizandrin (25, 50, 100, and 200 mumol L(-1)) could inhibit the activation of NLRP3 inflammasome caused by nigericin and ATP, and inhibit the secretion of IL-1beta, which was associated with inhibiting the cleavage of pro-caspase-1.	schizandrin A	0-16	interleukin 1 beta	Homo sapiens	161-169
29911779-7	2017	Deoxyschizandrin (25, 50, 100, and 200 mumol L(-1)) could inhibit the activation of NLRP3 inflammasome caused by nigericin and ATP, and inhibit the secretion of IL-1beta, which was associated with inhibiting the cleavage of pro-caspase-1.	schizandrin A	0-16	caspase 1	Homo sapiens	228-237
29911779-9	2017	Our results confirmed that deoxyschizandrin could suppress the cleavage of pro-caspase-1 and inhibit the activity of NLRP3 inflammasome at 25-200 mumol L-1 to reduce the inflammation response.This study was conducted to investigate the inhibitory effect and the molecular mechanism of deoxyschizandrin on the activity of NLRP3 (NOD-like receptor family,pyrin domain containing 3) inflammasome.Bone marrow-derived macrophages were used to study the effects of deoxyschizandrin on inflammasome activation using inflammasome inducers (ATP and nigericin).	schizandrin A	27-43	caspase 1	Homo sapiens	79-88
29911779-9	2017	Our results confirmed that deoxyschizandrin could suppress the cleavage of pro-caspase-1 and inhibit the activity of NLRP3 inflammasome at 25-200 mumol L-1 to reduce the inflammation response.This study was conducted to investigate the inhibitory effect and the molecular mechanism of deoxyschizandrin on the activity of NLRP3 (NOD-like receptor family,pyrin domain containing 3) inflammasome.Bone marrow-derived macrophages were used to study the effects of deoxyschizandrin on inflammasome activation using inflammasome inducers (ATP and nigericin).	schizandrin A	27-43	NLR family pyrin domain containing 3	Homo sapiens	117-122
29911779-9	2017	Our results confirmed that deoxyschizandrin could suppress the cleavage of pro-caspase-1 and inhibit the activity of NLRP3 inflammasome at 25-200 mumol L-1 to reduce the inflammation response.This study was conducted to investigate the inhibitory effect and the molecular mechanism of deoxyschizandrin on the activity of NLRP3 (NOD-like receptor family,pyrin domain containing 3) inflammasome.Bone marrow-derived macrophages were used to study the effects of deoxyschizandrin on inflammasome activation using inflammasome inducers (ATP and nigericin).	schizandrin A	27-43	NLR family pyrin domain containing 3	Homo sapiens	321-326
29911779-9	2017	Our results confirmed that deoxyschizandrin could suppress the cleavage of pro-caspase-1 and inhibit the activity of NLRP3 inflammasome at 25-200 mumol L-1 to reduce the inflammation response.This study was conducted to investigate the inhibitory effect and the molecular mechanism of deoxyschizandrin on the activity of NLRP3 (NOD-like receptor family,pyrin domain containing 3) inflammasome.Bone marrow-derived macrophages were used to study the effects of deoxyschizandrin on inflammasome activation using inflammasome inducers (ATP and nigericin).	schizandrin A	285-301	NLR family pyrin domain containing 3	Homo sapiens	117-122
27195753-4	2016	The greater activity of Sch A in anti-inflammatory response was associated with a greater decrease in cellular reduced glutathione (GSH) level and a greater increase in glutathione S-transferase activity than corresponding changes produced by Sch B.	schizandrin A	24-29	hematopoietic prostaglandin D synthase	Mus musculus	169-194
26919063-0	2016	Schizandrin A Inhibits Microglia-Mediated Neuroninflammation through Inhibiting TRAF6-NF-kappaB and Jak2-Stat3 Signaling Pathways.	schizandrin A	0-13	TNF receptor-associated factor 6	Mus musculus	80-85
26919063-0	2016	Schizandrin A Inhibits Microglia-Mediated Neuroninflammation through Inhibiting TRAF6-NF-kappaB and Jak2-Stat3 Signaling Pathways.	schizandrin A	0-13	Janus kinase 2	Mus musculus	100-104
26919063-0	2016	Schizandrin A Inhibits Microglia-Mediated Neuroninflammation through Inhibiting TRAF6-NF-kappaB and Jak2-Stat3 Signaling Pathways.	schizandrin A	0-13	signal transducer and activator of transcription 3	Mus musculus	105-110
26919063-6	2016	Investigations of the mechanism showed the anti-inflammatory effect of Sch A involved the inhibition of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) expression levels and inhibition of the LPS-induced TRAF6-IKKbeta-NF-kappaB pathway.	schizandrin A	71-76	nitric oxide synthase 2, inducible	Mus musculus	104-135
26919063-6	2016	Investigations of the mechanism showed the anti-inflammatory effect of Sch A involved the inhibition of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) expression levels and inhibition of the LPS-induced TRAF6-IKKbeta-NF-kappaB pathway.	schizandrin A	71-76	nitric oxide synthase 2, inducible	Mus musculus	137-141
26919063-6	2016	Investigations of the mechanism showed the anti-inflammatory effect of Sch A involved the inhibition of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) expression levels and inhibition of the LPS-induced TRAF6-IKKbeta-NF-kappaB pathway.	schizandrin A	71-76	prostaglandin-endoperoxide synthase 2	Mus musculus	147-163
26919063-6	2016	Investigations of the mechanism showed the anti-inflammatory effect of Sch A involved the inhibition of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) expression levels and inhibition of the LPS-induced TRAF6-IKKbeta-NF-kappaB pathway.	schizandrin A	71-76	prostaglandin-endoperoxide synthase 2	Mus musculus	165-170
26919063-6	2016	Investigations of the mechanism showed the anti-inflammatory effect of Sch A involved the inhibition of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) expression levels and inhibition of the LPS-induced TRAF6-IKKbeta-NF-kappaB pathway.	schizandrin A	71-76	TNF receptor-associated factor 6	Mus musculus	224-229
26919063-6	2016	Investigations of the mechanism showed the anti-inflammatory effect of Sch A involved the inhibition of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) expression levels and inhibition of the LPS-induced TRAF6-IKKbeta-NF-kappaB pathway.	schizandrin A	71-76	inhibitor of kappaB kinase beta	Mus musculus	230-237
25975095-7	2015	We found that schisandrin A and B increased OATP1B1 mRNA levels by 1.81-fold (p < 0.01) and 1.87-fold (p < 0.01) at concentration of 10 muM, respectively.	schizandrin A	14-27	solute carrier organic anion transporter family member 1B1	Homo sapiens	44-51
25975095-7	2015	We found that schisandrin A and B increased OATP1B1 mRNA levels by 1.81-fold (p < 0.01) and 1.87-fold (p < 0.01) at concentration of 10 muM, respectively.	schizandrin A	14-27	latexin	Homo sapiens	142-145
25975095-8	2015	Schisandrin A of 1 muM and 10 muM and schisandrin B of 10 muM significantly increased the uptake of [3H] estrone-3-sulfate (p < 0.05 or p < 0.01).	schizandrin A	0-13	latexin	Homo sapiens	19-22
24855828-8	2014	Isoalantolactone and schisandrin A are potent inhibitors of CYP2C19, while curcumol is a moderate potent inhibitor of CYP2C19.	schizandrin A	21-34	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	60-67
24786236-6	2014	Among the 63 phytochemicals screened, 6 compounds, including coptisine sulfate, bilobalide, schizandrin B, luteolin, schizandrin A and puerarin, at 100 mumol/L inhibited CYP2D6(*)1- and CYP2D6(*)10-mediated O-demethylation of a coumarin compound AMMC by more than 50%.	schizandrin A	117-130	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	170-176
24992201-7	2014	RESULTS: Aspartate amino-transferase (AST) and alanine transaminase (ALT) levels in the schisandrin A group were significantly decreased (p < 0.01) compared with those in the d-GalN-treated group.	schizandrin A	88-101	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	9-36
24992201-7	2014	RESULTS: Aspartate amino-transferase (AST) and alanine transaminase (ALT) levels in the schisandrin A group were significantly decreased (p < 0.01) compared with those in the d-GalN-treated group.	schizandrin A	88-101	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	38-41
24992201-7	2014	RESULTS: Aspartate amino-transferase (AST) and alanine transaminase (ALT) levels in the schisandrin A group were significantly decreased (p < 0.01) compared with those in the d-GalN-treated group.	schizandrin A	88-101	glutamic pyruvic transaminase, soluble	Mus musculus	47-67
24992201-7	2014	RESULTS: Aspartate amino-transferase (AST) and alanine transaminase (ALT) levels in the schisandrin A group were significantly decreased (p < 0.01) compared with those in the d-GalN-treated group.	schizandrin A	88-101	glutamic pyruvic transaminase, soluble	Mus musculus	69-72
24992201-7	2014	RESULTS: Aspartate amino-transferase (AST) and alanine transaminase (ALT) levels in the schisandrin A group were significantly decreased (p < 0.01) compared with those in the d-GalN-treated group.	schizandrin A	88-101	galanin and GMAP prepropeptide	Mus musculus	180-184
24992201-8	2014	HE results showed that the pathological changes in hepatic tissue seen in the d-GalN-treated were reduced in the schisandrin A/d-GalN-treated group, with the morphological characteristics being close to those of the control (untreated) group.	schizandrin A	113-126	galanin and GMAP prepropeptide	Mus musculus	80-84
24992201-8	2014	HE results showed that the pathological changes in hepatic tissue seen in the d-GalN-treated were reduced in the schisandrin A/d-GalN-treated group, with the morphological characteristics being close to those of the control (untreated) group.	schizandrin A	113-126	galanin and GMAP prepropeptide	Mus musculus	129-133
24986222-4	2014	In the present study, we sought to evaluate the neuroprotective effects of schizandrin A, a composition of S. chinesis Baill, against oxygen and glucose deprivation followed by reperfusion (OGD/R)-induced cell death in primary culture of rat cortical neurons, and to test whether C3a and C5a affected cortical neuron recovery from ischemic injury after schizandrin A treatment.	schizandrin A	75-88	complement C5	Rattus norvegicus	288-291
24986222-7	2014	C5aR participated in the neuroprotective effect of schizandrin A in primary culture of rat cortical neurons after OGD/R.	schizandrin A	51-64	complement C5a receptor 1	Rattus norvegicus	0-4
24475039-7	2014	Combined treatment of lignans with SC-2 enhanced the intracellular transport of schisandrin B and deoxyschisandrin but decreased that of gomisin C, resulting in alteration of cell-killing bioactivity.	schizandrin A	98-114	trans-2,3-enoyl-CoA reductase	Homo sapiens	35-39
24131672-2	2014	In the present study, the oxidative pathways of deoxyschizandrin (DS), the most abundant lignan in Fructus Schisandrae fruit extract, were characterized with liver microsomes from human (HLM) and rat (RLM).	schizandrin A	48-64	oxysterol binding protein 2	Homo sapiens	187-190
24131672-11	2014	These results show that DS is a good representative substrate of MDZ and TST primarily due to their shared, large binding regions on CYP3A.	schizandrin A	24-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-138
24131672-2	2014	In the present study, the oxidative pathways of deoxyschizandrin (DS), the most abundant lignan in Fructus Schisandrae fruit extract, were characterized with liver microsomes from human (HLM) and rat (RLM).	schizandrin A	66-68	oxysterol binding protein 2	Homo sapiens	187-190
24131672-12	2014	Therefore, DS is an attractive candidate as a novel CYP3A probe substrate for predicting the metabolic modifications in CYP3A activity.	schizandrin A	11-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-57
24131672-12	2014	Therefore, DS is an attractive candidate as a novel CYP3A probe substrate for predicting the metabolic modifications in CYP3A activity.	schizandrin A	11-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-125
24131672-4	2014	CYP3A4 and CYP3A5 were found to be the major isoforms involved in the monohydroxylation of DS.	schizandrin A	91-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
24131672-4	2014	CYP3A4 and CYP3A5 were found to be the major isoforms involved in the monohydroxylation of DS.	schizandrin A	91-93	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	11-17
23339253-0	2012	Strong inhibition of deoxyschizandrin and schisantherin A toward UDP-glucuronosyltransferase (UGT) 1A3 indicating UGT inhibition-based herb-drug interaction.	schizandrin A	21-37	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	65-102
23691032-10	2013	The most active adiponectin receptor 2 agonists are parthenolide, taxifoliol, deoxyschizandrin, and syringin.	schizandrin A	78-94	adiponectin receptor 2	Homo sapiens	16-38
23339253-0	2012	Strong inhibition of deoxyschizandrin and schisantherin A toward UDP-glucuronosyltransferase (UGT) 1A3 indicating UGT inhibition-based herb-drug interaction.	schizandrin A	21-37	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	94-97
23339253-6	2012	Furthermore, deoxyschizandrin and schisantherin Awere demonstrated to inhibit UGT1A3 in a concentration-dependent manner, with IC50 valueof 10.8+-0.4 muM and 12.5+-0.5 muM, respectively.	schizandrin A	13-29	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	78-84
20448858-0	2010	Inhibitory effects of schisandrin A and schisandrin B on CYP3A activity.	schizandrin A	22-35	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	57-62
21895978-0	2012	Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat.	schizandrin A	46-59	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	63-68
21895978-1	2012	The objective of this study was to evaluate the ability of schisandrin A (SchA) to inhibit the P450 enzyme CYP3A in vivo.	schizandrin A	59-72	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	107-112
21895978-1	2012	The objective of this study was to evaluate the ability of schisandrin A (SchA) to inhibit the P450 enzyme CYP3A in vivo.	schizandrin A	74-78	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	107-112
21351579-16	2010	And schisandrin A, schisandrin B and schisandrol B showed significant inductive effect on the expression of rat CYP3A1 mRNA.	schizandrin A	4-17	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	112-118
20664957-6	2010	In flow cytometry assay using Annexin V and propidium iodide, deoxyschisandrin inhibited H2O2-induced apoptotic cell death.	schizandrin A	62-78	annexin A5	Homo sapiens	30-39
20664957-8	2010	Deoxyschisandrin inhibited H2O2-induced caspase-3 activation by blocking cleavage of pro-caspase-3.	schizandrin A	0-16	caspase 3	Homo sapiens	40-49
20664957-8	2010	Deoxyschisandrin inhibited H2O2-induced caspase-3 activation by blocking cleavage of pro-caspase-3.	schizandrin A	0-16	caspase 3	Homo sapiens	85-98
20664957-11	2010	On the contrary, deoxyschisandrin inhibited H2O2-stimulated degradation of IkappaBalpha and activation of NF-kappaB by blocking translocation of NF-kappaB to the nucleus.	schizandrin A	17-33	NFKB inhibitor alpha	Homo sapiens	75-87
20664957-11	2010	On the contrary, deoxyschisandrin inhibited H2O2-stimulated degradation of IkappaBalpha and activation of NF-kappaB by blocking translocation of NF-kappaB to the nucleus.	schizandrin A	17-33	nuclear factor kappa B subunit 1	Homo sapiens	106-115
20664957-11	2010	On the contrary, deoxyschisandrin inhibited H2O2-stimulated degradation of IkappaBalpha and activation of NF-kappaB by blocking translocation of NF-kappaB to the nucleus.	schizandrin A	17-33	nuclear factor kappa B subunit 1	Homo sapiens	145-154
21351579-1	2010	This study is to investigate the effects of aqueous extract of Schisandra chinensis Baill (WWZ), kadsurin, schisandrin A, schisandrin B and schisandrol B on rat hepatic CYP3A.	schizandrin A	107-120	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	169-174
20628932-1	2010	Eighteen schizandrin A derivatives, possessing an acyl group at 7-OH and/or halogen(s) at C-4 and C-11, were designed and synthesized for evaluation of their in vitro ability to inhibit multidrug resistance (MDR).	schizandrin A	9-22	complement C4A (Rodgers blood group)	Homo sapiens	90-102
20448858-1	2010	Our aim was to investigate the inhibitory effects of schisandrin A and schisandrin B on cytochrome P450 (CYP3A) activity in rat liver microsomes and the mechanism of this interaction.	schizandrin A	53-66	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	105-110
20448858-3	2010	Results showed that schisandrin A and schisandrin B inhibited CYP3A activity with IC(50) values of 6.60 and 5.51 microM and K(i) values of 5.83 and 4.24 microM, respectively.	schizandrin A	20-33	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	62-67
20448858-5	2010	The inactivation of CYP3A activity by schisandrin A and schisandrin B was found to be both time-and concentration-dependent (schisandrin A: K(I) = 4.51 microM, K(inact) = 0.134/min; schisandrin B: K(I) = 3.01 microM, K(inact) = 0.112/min).	schizandrin A	38-51	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	20-25
20448858-5	2010	The inactivation of CYP3A activity by schisandrin A and schisandrin B was found to be both time-and concentration-dependent (schisandrin A: K(I) = 4.51 microM, K(inact) = 0.134/min; schisandrin B: K(I) = 3.01 microM, K(inact) = 0.112/min).	schizandrin A	125-138	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	20-25
20448858-6	2010	We conclude that the inhibition of CYP3A activity in rat liver microsomes by schisandrin A and schisandrin B is mostly attributed to a mixed noncompetitive and complete inhibition.	schizandrin A	77-90	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	35-40